Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (DE:51S)
FRANKFURT:51S
RESEARCH TOOLSreports
Holding DE:51S?
Track your performance easily
51S Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.07 - €0.19
Previous CloseN/A
Volume0.00
Average Volume (3M)130.00
Market Cap
$30.42M
Enterprise Value€46.79M
Total Cash (Recent Filing)$10.35M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.93
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding225,245,710
10 Day Avg. Volume0
30 Day Avg. Volume130
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cynata Therapeutics Limited News
PremiumCompany Announcements
Cynata Therapeutics to Present at Biotech Showcase™
PremiumCompany Announcements
Cynata Therapeutics Sees Change in Substantial Shareholder Voting Power
PremiumCompany Announcements
Cynata Therapeutics Announces Key Shareholder Meeting and Trial UpdatesPremiumCompany Announcements
Cynata Therapeutics Raises $8.1M After Positive Trial Results
PremiumCompany Announcements
Cynata’s CYP-006TK Shows Promise in Diabetic Foot Ulcer Trial
PremiumCompany Announcements
Cynata Therapeutics Requests ASX Trading Halt
PremiumCompany Announcements
Cynata Therapeutics’ AGM Approves Key ResolutionsPremiumCompany Announcements
Cynata Therapeutics Marks Strong Progress and Share Recovery51S FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was €0.07 and its highest was €0.18 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is $30.42M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Feb 20, 2025 which is in 36 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Aug 29, 2024. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.018.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 225,245,710 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -€0.018 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:51S
---
Cynata Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:51S Sentiment 92%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.66%
12-Months-Change
Fundamentals
Return on Equity
-80.05%
Trailing 12-Months
Asset Growth
-55.69%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which has branded Cymerus.
---
Technical Analysis
Cynata Therapeutics Limited
―
Capricor Therapeutics
―
Novartis
―
Alnylam Pharma
―
Adverum Biotechnologies
―
Immuron
―
---